Canaccord Genuity Reiterates Buy Rating on AbbVie Inc. (ABBV)

Market Context

AbbVie Inc. operates in the Healthcare sector. The stock currently trades at $252.65 with a market capitalization of $410.1B. The stock has gained 9.8% over the past 52 weeks.

Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for AbbVie Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for AbbVie Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 22, 2026	Canaccord Genuity	Buy	N/A
Jul 15, 2026	Citigroup	Neutral	N/A
Jul 13, 2026	UBS	Neutral	N/A
Jul 13, 2026	BMO Capital	Outperform	N/A
Jul 10, 2026	B of A Securities	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View ABBV Stock Page